ArticleJournal of laboratory physicians2013
Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?
Article in Journal of laboratory physicians, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Fluoroquinolone-Associated Tendinopathy of the Hand and Wrist: A Systematic Review and Case Report.Hand (New York, N.Y.) · 2017Pooled it
- Parenteral Vancomycin in the Treatment of MRSA-Associated Diabetic Foot Infections: An Unnecessary Risk.The international journal of lower extremity wounds · 2026Review
- Prevalence, Antimicrobial Resistance, and Molecular Characteristics of MRSA in Saudi Arabia: A Retrospective Study.Microorganisms · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Correlation of QRDR mutations and MIC levels in fluoroquinolone-resistantMicrobiology spectrum · 2025Article
- Post-fluoroquinolone treatment molecular events and nutrient availability modulatebioRxiv : the preprint server for biology · 2025Article
- Molecular detection ofIn silico pharmacology · 2025Article
- Article
- A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.Antimicrobial agents and chemotherapy · 2024Article
- Antimicrobial, Anti-inflammatory, and Wound Healing Properties ofBioMed research international · 2024Article
- New Antibiotics forAntibiotics (Basel, Switzerland) · 2023Review
- Isoquinoline Antimicrobial Agent: Activity against Intracellular Bacteria and Effect on Global Bacterial Proteome.Molecules (Basel, Switzerland) · 2022Article
- Article
- Vinyl halogenated fatty acids display antibacterial activity against clinical isolates of methicillin-resistantMedical research archives · 2022Article
- Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2022Article
- The prevalence ofSaudi journal of biological sciences · 2021Article
- Bio-evaluation of fluoro and trifluoromethyl-substituted salicylanilides against multidrug-resistantMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021Article
- Acquisition Risk Factors of the SCCAntibiotics (Basel, Switzerland) · 2020Article
- A Narrative Review of Early Oral Stepdown Therapy for the Treatment of UncomplicatedOpen forum infectious diseases · 2020Review
- Plant Secondary Metabolites in the Battle of Drugs and Drug-Resistant Bacteria: New Heroes or Worse Clones of Antibiotics?Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe study aimed to evaluate the utility of various commonly used fluoroquinolones against Staphylococcus aureus isolates. MATERIALS AND
methodsA total of 250 isolates of S. aureus were studied from different clinical specimens like blood, pus, wound swabs, sputum, ear swabs, and body fluids between November 2009 and December 2011. All the isolates were tested for their susceptibility to fluoroquinolones and other antimicrobial agents by Kirby-Bauer disc diffusion method using criteria of standard zone of inhibition. Methicillin-resistant S. aureus (MRSA) detection was done by cefoxitin disk diffusion method. The MRSA isolates were tested for minimum inhibitory concentration (MIC) to vancomycin by E-test strips. All the MRSA strains were sent to National Staphylococcal Phage-typing Centre, Maulana Azad Medical College, New Delhi for phage typing.
resultsA total of 107 strains of S. aureus (42.8%) were detected as MRSA. Multidrug resistance was observed among the MRSA strains more commonly than among the MSSA stains. Among the fluoroquinolones, maximum resistance in MRSA was seen to ciprofloxacin (92.5%), followed by ofloxacin (80.4%). None of the S. aureus isolates showed resistance to vancomycin and linezolid. The MICs of vancomycin for the MRSA tested ranged from 0.5 to 2 μg/ml. Phage typing pattern of 107 MRSA isolates revealed that 37 (34.6%) MRSA isolates were nontypeable and 70 (65.4%) were typeable.
conclusionCiprofloxacin can no longer be used in empirical therapy against MRSA infections. Use of other members of fluoroquinolone should be limited only to those strains that show laboratory confirmation of their susceptibility. Vancomycin remains the drug of choice to treat MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.